Archives of Obesity and Metabolism (비만대사연구학술지)

The Study of Obesity and Metabolic Syndrome, KAFM (대한가정의학회 비만대사증후군연구회)
권호 표지
DOI QR코드

DOI QR Code

When Should Familial Hypercholesterolemia Be Suspected?: A Case of Dyslipidemia in Young Patient without Coronary Artery Disease

가족성 고콜레스테롤혈증은 언제 의심해야 할까?: 관상동맥 질환이 없는 젊은 이상지질혈증 환자 증례

  • In Sun Ryou (Department of Family Medicine, Ewha Womans University Seoul Hospital)
  • 유인선 (이화여자대학교 의과대학 부속 서울병원 가정의학과)
  • Received : 2023.03.01
  • Accepted : 2023.05.27
  • Published : 2023.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Familial hypercholesterolemia (FH) is a genetic disease that is not well known or diagnosed in Korea. This disease is associated with persistently high levels of low-density lipoprotein cholesterol (LDL-C), which increase the risk of coronary artery disease at a young age. Therefore, early diagnosis and treatment are important; however, there are no global consensus diagnostic criteria. In Korea, the Dutch Lipid Clinic Network diagnostic criteria, and the Simon Broome diagnostic criteria were used for diagnosis of FH according to the agreement announced at the Korean Society of Lipid and Atherosclerosis (KSoLA) in 2022. Recently, the absence of coronary artery calcification has been considered a good prognostic factor, even among patients with very high LDL-C levels who are considered to be at high risk for atherosclerotic cardiovascular disease. We describe throughout this paper the diagnosis and treatment of FH in a young male without coronary artery calcification.

Keywords

References

  1. Schmidt EB, Hedegaard BS, Retterstol K. Familial hypercholesterolaemia: history, diagnosis, screening, management and challenges. Heart 2020;106:1940-6. https://doi.org/10.1136/heartjnl-2019-316276
  2. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205. Erratum in: Atherosclerosis 2020;292:160-2. Erratum in: Atherosclerosis 2020;294:80-2. https://doi.org/10.1016/j.atherosclerosis.2019.12.004
  3. Lee CJ, Yoon M, Kang HJ, et al. 2022 Consensus statement on the management of familial hypercholesterolemia in Korea. Korean J Med 2022;97:339-52. https://doi.org/10.3904/kjm.2022.97.6.339
  4. Gallo A, Giral P, Carrie A, et al. Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia. J Clin Lipidol 2017;11:704-11.e2. https://doi.org/10.1016/j.jacl.2017.03.016
  5. Johnson KW, Dudley JT, Bobe JR. A 72-year-old patient with longstanding, untreated familial hypercholesterolemia but no coronary artery calcification: a case report. Cureus 2018;10:e2452.
  6. Kim H, Lee CJ, Kim SH, et al. Phenotypic and genetic analyses of Korean patients with familial hypercholesterolemia: results from the KFH registry 2020. J Atheroscler Thromb 2022;29:1176-87. https://doi.org/10.5551/jat.63062
  7. Duell PB, Gidding SS, Andersen RL, et al. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry. Atherosclerosis 2019;289:85-93. https://doi.org/10.1016/j.atherosclerosis.2019.08.007
  8. Trinder M, Francis GA, Brunham LR. Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease. JAMA Cardiol 2020;5:390-9. Erratum in: JAMA Cardiol 2020;5:488.
  9. Mszar R, Grandhi GR, Valero-Elizondo J, et al. Absence of coronary artery calcification in middle-aged familial hypercholesterolemia patients without atherosclerotic cardiovascular disease. JACC Cardiovasc Imaging 2020;13:1090-2. https://doi.org/10.1016/j.jcmg.2019.11.001
  10. Nasir K. Message for 2018 cholesterol management guidelines update: time to accept the power of zero. J Am Coll Cardiol 2018;72:3243-5. https://doi.org/10.1016/j.jacc.2018.10.006
  11. Miname MH, Bittencourt MS, Moraes SR, et al. Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy. JACC Cardiovasc Imaging 2019;12:1797-804. https://doi.org/10.1016/j.jcmg.2018.09.019
  12. Garg PK, Jorgensen NW, McClelland RL, et al. Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA). J Cardiovasc Comput Tomogr 2018;12:493-9. https://doi.org/10.1016/j.jcct.2018.10.001
  13. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331-40. https://doi.org/10.1016/S0140-6736(14)61399-4
  14. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. https://doi.org/10.1056/NEJMoa1615664
  15. O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 2022;146:1109-19. https://doi.org/10.1161/CIRCULATIONAHA.122.061620